Published in J Vasc Interv Radiol on July 01, 2006
Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol (2007) 2.07
The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol (2009) 1.11
Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. Liver Cancer (2012) 1.02
Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol (2010) 1.00
Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol (2006) 0.99
Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol (2009) 0.96
Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol (2010) 0.93
Diffusion-weighted MRI in abdominal oncology: clinical applications. World J Gastroenterol (2010) 0.89
Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol (2010) 0.87
Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed (2016) 0.83
Diffusion-weighted imaging of the liver: an update. Cancer Imaging (2013) 0.82
Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2015) 0.82
Applications of molecular imaging. Prog Mol Biol Transl Sci (2010) 0.81
Quantitative multiparametric PROPELLER MRI of diethylnitrosamine-induced hepatocarcinogenesis in wister rat model. J Magn Reson Imaging (2010) 0.80
Diffusion-weighted imaging of the liver: techniques and applications. Magn Reson Imaging Clin N Am (2014) 0.76
Prognostication and response assessment in liver and pancreatic tumors: The new imaging. World J Gastroenterol (2015) 0.76
Functional magnetic resonance imaging in an animal model of pancreatic cancer. World J Gastroenterol (2010) 0.76
Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. Onco Targets Ther (2016) 0.75
Hepatocellular carcinoma: IVIM diffusion quantification for prediction of tumor necrosis compared to enhancement ratios. Eur J Radiol Open (2015) 0.75
Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging (2014) 0.75
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys (2007) 3.65
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol (2008) 1.84
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology (2014) 1.78
Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology (2003) 1.73
Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol (2007) 1.73
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Accidental ureteral ligation during an inguinal hernia repair of patient with crossed fused renal ectopia. Clin Imaging (2002) 1.70
Peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy produce a similar short-term anatomic and functional effect. Surgery (2013) 1.70
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol (2006) 1.68
Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol (2006) 1.64
Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol (2011) 1.64
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Transcatheter intraarterial therapies: rationale and overview. Radiology (2011) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol (2005) 1.58
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res (2010) 1.56
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55
Complications of renal transplantation. Radiographics (2005) 1.55
Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol (2005) 1.54
Automated rectilinear self-gated cardiac cine imaging. Magn Reson Med (2004) 1.52
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
ACR Appropriateness Criteria® right lower quadrant pain--suspected appendicitis. J Am Coll Radiol (2011) 1.51
Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol (2007) 1.51
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys (2009) 1.51
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. Cardiovasc Intervent Radiol (2004) 1.48
Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol (2013) 1.47
Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surg Neurol (2005) 1.46
Optional or permanent: clinical factors that optimize inferior vena cava filter utilization. J Vasc Interv Radiol (2012) 1.46
Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol (2010) 1.46
Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol (2007) 1.45
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology (2008) 1.45
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Primary failure of uterine artery embolization: use of magnetic resonance imaging to select patients for repeated embolization. J Vasc Interv Radiol (2005) 1.43
Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol (2009) 1.43